Veliparib Plus Temozolomide for MGMT-Methylated Glioblastoma-Reply

被引：0
|
作者：
Sarkaria, Jann N. [1 ]
Kizilbash, Sani H. [1 ]
Giannini, Caterina [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
JAMA ONCOLOGY | 2025年
关键词：
D O I：
10.1001/jamaoncol.2025.0032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
    Sim, Hao-Wen
    McDonald, Kerrie L.
    Lwin, Zarnie
    Barnes, Elizabeth H.
    Rosenthal, Mark
    Foote, Matthew C.
    Koh, Eng-Siew
    Back, Michael
    Wheeler, Helen
    Sulman, Erik P.
    Buckland, Michael E.
    Fisher, Lauren
    Leonard, Robyn
    Hall, Merryn
    Ashley, David M.
    Yip, Sonia
    Simes, John
    Khasraw, Mustafa
    NEURO-ONCOLOGY, 2021, 23 (10) : 1736 - 1749
  • [22] Differential radiosensitizing potential of temozolomide in mgmt promoter methylated glioblastoma multiforme cell lines
    Van Nifterik, Krista A.
    Van den Berg, Jaap
    Stalpers, Lukas J. A.
    Lafleur, M. Vincent M.
    Leenstra, Sieger
    Slotman, Ben J.
    Hulsebos, Theo J. M.
    Sminia, Peter
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (04): : 1246 - 1253
  • [23] Radiation plus Temozolomide in Patients with Glioblastoma Reply
    Perry, James R.
    Laperriere, Normand
    Mason, Warren P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (22): : 2197 - 2197
  • [24] MGMT INHIBITION BY DISULFIRAM/COPPER COMPLEX RESTORES VELIPARIB ENHANCING TEMOZOLOMIDE EFFECT IN UNFAVORABLE GLIOBLASTOMA MULTIFORME
    Bobustuc, George
    Donohoe, Deborah
    Bosenko, Dmitry
    Rovin, Richard
    Kassam, Amin
    Konduri, Santhi
    NEURO-ONCOLOGY, 2017, 19 : 77 - 77
  • [25] Combination Therapy of Lomustine and Temozolomide in Patients with newly diagnosed Glioblastoma with methylated MGMT Promotor
    Lenzen, Julia
    Feldmann, H. J.
    ONKOLOGE, 2019, 25 (12): : 1118 - 1120
  • [26] Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT
    Alvarez-Torres, Maria del Mar
    Fuster-Garcia, Elies
    Balana, Carmen
    Puig, Josep
    Garcia-Gomez, Juan M.
    CANCERS, 2021, 13 (21)
  • [27] EGFRvIII: A NEW PREDICTIVE BIOMARKER FOR TEMOZOLOMIDE RESPONSE IN MGMT PROMOTOR METHYLATED GLIOBLASTOMA PATIENTS
    Struve, Nina
    Brend, Tim
    Stead, Lucy
    Binder, Zev A.
    Ott, Leonie
    Muller-Goebel, Justus
    Hoffer, Konstatin
    Morrissette, Jennifer J. D.
    Petersen, Cordula
    Rothkamm, Kai
    O'Rourke, Donald
    Short, Susan C.
    Kriegs, Malte
    NEURO-ONCOLOGY, 2017, 19 : 84 - 84
  • [28] A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed MGMT-methylated malignant glioma
    Driscoll, Riley K.
    Lyne, Sean B.
    Voce, David J.
    Maraka, Stefania
    Gondi, Vinai
    Chmura, Steven J.
    Dixit, Karan S.
    Kumthekar, Priya U.
    Karrison, Theodore G.
    Pytel, Peter
    Collins, John M.
    Stupp, Roger
    Merrell, Ryan T.
    Lukas, Rimas, V
    Yamini, Bakhtiar
    NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
  • [29] Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial
    Zeyen, Thomas
    Potthoff, Anna-Laura
    Nemeth, Robert
    Heiland, Dieter H.
    Burger, Michael C.
    Steinbach, Joachim P.
    Hau, Peter
    Tabatabai, Ghazaleh
    Glas, Martin
    Schlegel, Uwe
    Grauer, Oliver
    Krex, Dietmar
    Schnell, Oliver
    Goldbrunner, Roland
    Sabel, Michael
    Thon, Niklas
    Delev, Daniel
    Clusmann, Hans
    Seidel, Clemens
    Gueresir, Erdem
    Schmid, Matthias
    Schuss, Patrick
    Giordano, Frank A.
    Radbruch, Alexander
    Becker, Albert
    Weller, Johannes
    Schaub, Christina
    Vatter, Hartmut
    Schilling, Judith
    Winkler, Frank
    Herrlinger, Ulrich
    Schneider, Matthias
    TRIALS, 2022, 23 (01)
  • [30] REGORAFENIB IN COMBINATION WITH TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT-METHYLATED, IDH WILDTYPE GLIOBLASTOMA: A PHASE I DOSE-FINDING STUDY (REGOMA-2)
    Padovan, Marta
    De Salvo, Gian Luca
    D'Avolio, Antonio
    Caccese, Mario
    Zagonel, Vittorina
    Lombardi, Giuseppe
    NEURO-ONCOLOGY, 2022, 24 : 73 - 73
12345